A randomized, double-blind, multicenter trial was conducted by Povsic et al. (published in 2016) to determine improvement in total exercise time (TET) and angina frequency in patients with refractory angina after autologous CD34+ cell administration [15]. This evidence concerns the gene CD34 and angina pectoris.